Overview

Bortezomib

CAS

179324-69-7

Status

Commercial

Bortezomib is a piperazine derivative that is the first representative of a new class of active ingredients, the proteasome inhibitors. Proteasomas are involved in the cell cycle and thus also regulate growth. If these are inhibited in tumor cells, various signals in the cell are removed, which in sum leads to the inhibition of tumor growth. It is approved for the monotherapy of progressive multiple myeloma in patients who have already received treatment or are not suitable for other therapies.

Description

Formula

C19H25BN4O4

Molecular weight

384.24 g/mol

Molecular size

small

Controlled Substance

no

Precursor

no

Indications

Antineoplastic drugs

Your Contact

Marius Hang

Marius Hang

International Division
Director API Export

Midas Pharma GmbH
Rheinstr. 49
55218 Ingelheim
Germany
  • Disclaimer

    The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.

    No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.

Complementary Services

Share this page